The Advanced Clinical Trial Workshop China (ACT China IV) was held successfully at Hilton Shekou Shenzhen, co-organized by CSCO, ASCO, Conquer Cancer Foundation and STO from November 20 to 23rd in 2014. The aim of ACT China is to attract and encourage more and more Chinese individual researchers and cancer centers engaged in an international level of clinic trials and researches.

ACT China IV continued with the high standards in the sessions of discussion and training in academic activities which is co-designed and guided by the well-known experts abroad and CSCO committee members. The invited faculties included Prof. J.Jack Lee from MD Anderson Cancer Center, Mr. Max Ning from FDA, Mr. Iordanis Gravanis from EMA drug evaluation department, Prof. Monica Marie Bertagnolli from Harvard University, Prof. Yi-Long Wu, Prof. Jin Li, Prof. Lin Qiu, Prof. Ning Liao, Prof. Qing Zhou and Prof. Xiaodong Zhu. It was highly regrettable that Prof. Martin Murphy (one of initiate member for ACT China, Honorary Chairman of ASCO Conquer Cancer Foundation) could not be there in person for health reasons, but he brought his greetings and greatest wishes via video.       

With the development of the ACT workshop, more and more oncologists will participate in the discussion and learning, which will effectively improve the level of clinical research in China, accelerate the Chinese tumor drug clinical research level in line with international standards.

Following is the agenda of the meeting,

ACT China IV_Agenda.pdf